Publicacións en colaboración con investigadores/as de Institut d'Investigació Biomédica de Bellvitge (26)

2024

  1. Exploring Biginelli-based scaffolds as A2B adenosine receptor antagonists: Unveiling novel structure-activity relationship trends, lead compounds, and potent colorectal anticancer agents

    Biomedicine and Pharmacotherapy, Vol. 173

  2. Update on the management of older patients with pancreatic adenocarcinoma: a perspective from medical oncology

    Clinical and Translational Oncology

2023

  1. Phase II Trial of Atezolizumab Combined With Carboplatin and Pemetrexed for Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer With Untreated Brain Metastases (Atezo-Brain, GECP17/05)

    Journal of Clinical Oncology, Vol. 41, Núm. 28, pp. 4478-4485

  2. SEOM-GEINO clinical guidelines for high-grade gliomas of adulthood (2022)

    Clinical and Translational Oncology, Vol. 25, Núm. 9, pp. 2634-2646

  3. Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer

    Lung Cancer, Vol. 178, pp. 116-122

2022

  1. Noninvasive early detection of colorectal cancer by hypermethylation of the LINC00473 promoter in plasma cell-free DNA

    Clinical Epigenetics, Vol. 14, Núm. 1

  2. Randomized phase 3 noninferiority trial of radiotherapy and cisplatin vs radiotherapy and cetuximab after docetaxel-cisplatin-fluorouracil induction chemotherapy in patients with locally advanced unresectable head and neck cancer

    Oral Oncology, Vol. 134

  3. Tumor microenvironment gene expression profiles associated to complete pathological response and disease progression in resectable NSCLC patients treated with neoadjuvant chemoimmunotherapy

    Journal for immunotherapy of cancer, Vol. 10, Núm. 9

2021

  1. Immune microenvironment characterisation and dynamics during anti-HER2-based neoadjuvant treatment in HER2-positive breast cancer

    npj Precision Oncology, Vol. 5, Núm. 1

2020

  1. Analysis of Killer Immunoglobulin-Like Receptor Genes in Colorectal Cancer

    Cells, Vol. 9, Núm. 2

  2. Looking for a better characterization of triple-negative breast cancer by means of circulating tumor cells

    Journal of Clinical Medicine, Vol. 9, Núm. 2

2019

  1. Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study

    Breast Cancer Research and Treatment, Vol. 174, Núm. 3, pp. 693-701

  2. Immunotherapy with checkpoint inhibitors in non-small cell lung cancer: insights from long-term survivors

    Cancer Immunology, Immunotherapy, Vol. 68, Núm. 3, pp. 341-352

2018

  1. ARole forCXCR4in peritonealandhematogenous ovarian cancer dissemination

    Molecular Cancer Therapeutics, Vol. 17, Núm. 2, pp. 532-543

  2. Genotype-based selection of treatment of patients with advanced colorectal cancer (SETICC): A pharmacogenetic-based randomized phase II trial

    Annals of Oncology, Vol. 29, Núm. 2, pp. 439-444

2017

  1. Chromatin remodelling and DNA repair genes are frequently mutated in endometrioid endometrial carcinoma

    International Journal of Cancer, Vol. 140, Núm. 7, pp. 1551-1563

  2. Genetic analysis of uterine aspirates improves the diagnostic value and captures the intra-tumor heterogeneity of endometrial cancers

    Modern Pathology, Vol. 30, Núm. 1, pp. 134-145

  3. Inflammatory markers and circulating extracellular matrix proteins in patients with chronic obstructive pulmonary disease and left ventricular diastolic dysfunction

    Clinical Respiratory Journal, Vol. 11, Núm. 6, pp. 859-866

  4. Obesity and menopause modify the epigenomic profile of breast cancer

    Endocrine-related cancer, Vol. 24, Núm. 7, pp. 351-363

  5. Oncogenic PIK3CA induces centrosome amplification and tolerance to genome doubling

    Nature Communications, Vol. 8, Núm. 1